Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC)

PURPOSE The purpose of this review was to assess the outcome of patients with non-Hodgkin's lymphoma (NHL) who achieve an incomplete or slow response to front-line chemotherapy and to determine whether salvage treatment with intensive combination chemotherapy with or without autologous bone marrow transplantation (ABMT) is successful in such patients. METHODS A comprehensive literature search of studies using combination chemotherapy for the front-line therapy of advanced-stage intermediate- and high-grade NHL and for salvage therapy of patients with a partial response (PR) was reviewed. RESULTS The median survival duration of patients with a PR ranged between 5 to 14 months, while the median survival duration of patients with a complete response (CR) was not reached in many studies. For patients in CR, the probability of survival at 24 months ranged between 0.79 to 1, while for patients in PR it ranged from 0 to 0.31. The rapidity of a response to front-line therapy was often found to be of prognostic importance. Patients who relapsed after a PR to front-line therapy had similar outcomes to intensive salvage therapy as those who relapsed after a CR. ABMT performed immediately after a PR to induction therapy, before progressive disease occurred, resulted in high CR rates in nonrandomized studies. CONCLUSION Patients with aggressive NHL who experience a PR or who respond slowly to front-line chemotherapy have a poor prognosis. Early introduction of dose-intensive salvage therapy before the development of progressive disease may benefit patients with a PR and requires testing in randomized clinical trials.

Download Full-text

Solitary CNS Metastasis on Initial Presentation of High Grade Serous Carcinoma of the Fallopian Tube

Case Reports in Obstetrics and Gynecology ◽

10.1155/2018/6930986 ◽

2018 ◽

Vol 2018 ◽

pp. 1-4 ◽

Cited By ~ 1

Author(s):

Felicity Harl ◽

Cassandra Niemi ◽

Lori Mankowski Gettle ◽

Paul Weisman ◽

Stephen Rose

Keyword(s):

Fallopian Tube ◽

Brain Lesion ◽

Primary Site ◽

Initial Presentation ◽

Serous Carcinoma ◽

High Grade ◽

Metastatic Adenocarcinoma ◽

Cns Metastasis ◽

Small Primary ◽

History Of

A 68-year-old woman presented with a three-week history of confusion and anomic aphasia. Imaging of her head demonstrated a single large left frontal mass. Pathology revealed metastatic adenocarcinoma of Müllerian origin. Subsequent surgery revealed a small primary site in a fallopian tube, high left para-aortic lymphadenopathy, and no disseminated intraperitoneal disease. This case was remarkable in that CNS metastasis was her presenting symptom and was restricted to a solitary brain lesion, and other disease sites were limited to retroperitoneal lymphadenopathy and a small fallopian tube primary.

Download Full-text

Primary mixed large cell neuroendocrine and high grade serous carcinoma of the endometrium

BMJ Case Reports ◽

10.1136/bcr-2020-234977 ◽

2020 ◽

Vol 13 (9) ◽

pp. e234977

Author(s):

Liesel Elisabeth Hardy ◽

Zia Chaudry ◽

King Wan ◽

Chloe Ayres

Keyword(s):

Abdominal Pain ◽

Neuroendocrine Carcinoma ◽

Pelvic Mass ◽

Large Cell ◽

Serous Carcinoma ◽

High Grade ◽

Second Line ◽

Vaginal Mass ◽

Loss Of Weight ◽

Line Chemotherapy

Endometrial large-cell neuroendocrine carcinoma admixed with a high-grade serous (HGS) adenocarcinoma is extremely rare with only one reported case in the literature. We present the second reported case in a 47-year-old woman who presented with abdominal pain, distension and loss of weight. On examination she had a fixed pelvic mass and vascular left vaginal mass. Imaging confirmed a 13 cm solid cystic rectouterine pelvic mass, omental disease and retroperitoneal lymphadenopathy. She underwent a modified posterior exenteration, partial posterior vaginectomy, omentectomy and Hartmanns procedure with suboptimal debulking. Histopathology revealed a stage 4B mixed carcinoma with large cell neuroendocrine (70%) and HGS carcinoma (30%). Eight cycles of adjuvant cisplatin and paclitaxel were given with a complete radiological and biochemical response after 7 months. Unfortunately, she developed widespread recurrence at 9 month and was offered second line chemotherapy.

Download Full-text

Fallopian Tube High-grade Serous Carcinoma With Intramucosal Spread and Presenting as a Malignancy on Pap Smear

International Journal of Gynecological Pathology ◽

10.1097/pgp.0b013e31829c728b ◽

2014 ◽

Vol 33 (4) ◽

pp. 443-448 ◽

Cited By ~ 7

Author(s):

Zuzana Kos ◽

Russell R. Broaddus ◽

Bojana Djordjevic

Keyword(s):

Fallopian Tube ◽

Pap Smear ◽

Serous Carcinoma ◽

High Grade

Download Full-text

Outcomes of Incidental Fallopian Tube High-Grade Serous Carcinoma and Serous Tubal Intraepithelial Carcinoma in Women at Low Risk of Hereditary Breast and Ovarian Cancer

International Journal of Gynecological Cancer ◽

10.1097/igc.0000000000000639 ◽

2016 ◽

Vol 26 (3) ◽

pp. 431-436 ◽

Cited By ~ 20

Author(s):

Wen Yee Chay ◽

W. Glenn McCluggage ◽

Cheng-Han Lee ◽

Martin Köbel ◽

Julie Irving ◽

...

Keyword(s):

Ovarian Cancer ◽

Fallopian Tube ◽

Low Risk ◽

Serous Carcinoma ◽

High Grade ◽

Breast And Ovarian Cancer ◽

Serous Tubal Intraepithelial Carcinoma ◽

Intraepithelial Carcinoma

Download Full-text

Validation of Revised FIGO Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum Based on a Single Histological Type

International Journal of Gynecological Cancer ◽

10.1097/igc.0000000000000736 ◽

2016 ◽

Vol 26 (6) ◽

pp. 1012-1019 ◽

Cited By ~ 5

Author(s):

Tayfun Toptas ◽

Elif Pestereli ◽

Onur Erol ◽

Selen Bozkurt ◽

Gulgun Erdogan ◽

...

Keyword(s):

Fallopian Tube ◽

Stage Iv ◽

Hazard Ratio ◽

Stage Iii ◽

Serous Carcinoma ◽

Study Cohort ◽

High Grade ◽

Subgroup Analyses ◽

Clinical Records ◽

Staging Classification

ObjectiveThis study aimed to evaluate the prognostic significance of revised International Federation of Gynecology and Obstetrics (FIGO2013) staging classification for cancer of the ovary, fallopian tube, and peritoneum in patients exhibiting high-grade serous histology.MethodsClinical records of patients with high-grade serous carcinoma who underwent primary surgery between 2007 and 2012 were reviewed retrospectively. Patients were reclassified according to the FIGO2013 criteria. Progression-free survival (PFS) and overall survival (OS) were calculated for each stage using Kaplan-Meier estimates and compared with the log-rank test.ResultsIn total, 125 patients were included in the analysis. The distribution of the study cohort according to the revised classification was as follows; stage I, 6 patients; stage II, 9 patients; stage III, 85 patients; and stage IV, 25 patients. Median follow-up time was 36 months (95% confidence interval [CI], 3–110). The median PFS and OS were 14 months (95% CI, 12.4–15.6) and 60 months (95% CI, 47.0–72.9), respectively. Both PFS and OS were significantly different among stages I, II, III, and IV (P < 0.01). Subgroup analyses for stage III disease also revealed significant differences in survival. The median PFS for stages IIIA1, IIIB, and IIIC was 56, 46, and 16 months, respectively (P < 0.01), and the median OS was 104, 95, and 60 months, respectively (P = 0.03). The outcomes of patients with stage IV disease differed slightly but nonsignificantly according to new substages. The median PFS for stages IVA and IVB was 12 and 6 months, respectively (hazard ratio, 1.16; 95% CI, 0.48–2.79; P = 0.72), and the median OS was 41 and 24 months, respectively (hazard ratio, 1.62; 95% CI, 0.58–4.55; P = 0.35). The study sample was insufficient in size for subgroup analyses in stages I and II.ConclusionsThe revised FIGO2013 staging system is highly prognostic for discriminating outcomes of patients with high-grade serous carcinoma across stages I to IV, in subgroups of stage III, but not in subgroups of stage IV.

Download Full-text